報價延遲最少15分鐘:2025/06/02 07:29 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.59 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-89.15/-0.62
|
|
企業價值
1.46B
|
| 資產負債 |
|
每股賬面淨值
3.63
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
16.72M
|
|
每股收益
0.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:29 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization. |